2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Sattva S. Neelapu, MD, a professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial (NCT03105336) with axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
At the 2021 ASH Annual Meeting and Exposition, updated findings from the ZUMA-5 trial were presented with at least 2 years of follow-up, Neelapu says. Altogether, 149 patients were treated on the study. Among the efficacy-evaluable population (n = 110), the complete response rate was 79% in patients with follicular lymphoma and 63% in patients with marginal zone lymphoma (MZL), Neelapu explains.
After a median follow-up of 30.9 months in the follicular lymphoma cohort, 57% of patients remain in ongoing response, and the estimated median PFS was about 39.6 months, Neelapu continues. In the MZL cohort, the median follow-up was 23.8 months and 50% of the patients remain in remission, Neelapu concludes.